Invivyd, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Invivyd, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.43M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $25.38M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 20, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.49M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($169.93M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($198.64M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($241.32M) | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | ($83.04M) | Mar 31, 2022 |
| FY2021 | Sep 30, 2021 | ($60.38M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | ($44.67M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($38.70M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($65.32M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.56M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($176.88M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($212.76M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($248.03M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($226.91M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($65.33M) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.31M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $137.25M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $158.66M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $179.21M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $182.89M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $21.99M | Mar 31, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.93M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $63.39M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $49.13M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $47.04M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $36.52M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.21M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.14M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($170.49M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($173.16M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($219.99M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($184.74M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($14.57M) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.0K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $140.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $615.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.71M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $84.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.88M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $129.52M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $229.18M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $383.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $620.09M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $117.38M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.34M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $61.98M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $51.71M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $27.20M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $62.07M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $13.08M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.54M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $67.54M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $177.47M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $355.97M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $558.02M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($65.25M) | Mar 23, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($954.48M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($901.99M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($732.07M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($533.43M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($292.11M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($65.32M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.69M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $69.35M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $200.64M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $92.08M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $542.22M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $114.99M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 281.99M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 119.84M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 110.16M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 109.04M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 110.78M | Mar 23, 2023 |
| FY2021 | Mar 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 5.59M | Mar 31, 2022 |